These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 9222066

  • 1. Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
    Spangler SK, Jacobs MR, Appelbaum PC.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():23-7. PubMed ID: 9222066
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
    Pankuch GA, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.
    Venezia RA, Yocum DM, Robbiano EM, Echols RM.
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1858-61. PubMed ID: 2178340
    [Abstract] [Full Text] [Related]

  • 5. Susceptibility of anaerobic bacteria to PD 131628.
    Nord CE, Hagelbäck A.
    Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):68-71. PubMed ID: 1314176
    [Abstract] [Full Text] [Related]

  • 6. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
    Burgess DS, Hastings RW.
    Diagn Microbiol Infect Dis; 2000 Sep; 38(1):37-41. PubMed ID: 11025182
    [Abstract] [Full Text] [Related]

  • 7. In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.
    Schaumann R, Funke M, Janssen E, Rodloff AC.
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3413-6. PubMed ID: 22430962
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
    Nord CE.
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of gemifloxacin (SB 265805) against anaerobes.
    Goldstein EJ, Citron DM, Warren Y, Tyrrell K, Merriam CV.
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2231-5. PubMed ID: 10471570
    [Abstract] [Full Text] [Related]

  • 10. [Activity of trovafloxacin and ten other antimicrobials against gram negative anaerobic bacilli].
    Chávez M, García López JL, Coronilla J, Bernal S, Valverde A, Martín Mazuelos E.
    Rev Esp Quimioter; 1998 Dec; 11(4):349-52. PubMed ID: 9990149
    [Abstract] [Full Text] [Related]

  • 11. [Bactericidal activity of Trovafloxacin and Moxifloxacin against Gram-negative anaerobic bacilli].
    Bosnea D, Stadoleanu C, Boswell FJ, Buiuc D.
    Rev Med Chir Soc Med Nat Iasi; 2000 Dec; 104(4):117-22. PubMed ID: 12089939
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of activities of trovafloxacin (CP-99,219) and five other agents against 585 anaerobes with use of three media.
    Hecht DW, Osmolski JR.
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S44-50. PubMed ID: 8953106
    [Abstract] [Full Text] [Related]

  • 14. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.
    Aldridge KE, Ashcraft D, Cambre K, Pierson CL, Jenkins SG, Rosenblatt JE.
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1238-43. PubMed ID: 11257040
    [Abstract] [Full Text] [Related]

  • 15. Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group.
    Falagas ME, McDermott L, Snydman DR.
    Antimicrob Agents Chemother; 1997 Sep; 41(9):2047-9. PubMed ID: 9303414
    [Abstract] [Full Text] [Related]

  • 16. Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods.
    Ednie LM, Credito KL, Khantipong M, Jacobs MR, Appelbaum PC.
    J Antimicrob Chemother; 2000 May; 45(5):633-8. PubMed ID: 10797085
    [Abstract] [Full Text] [Related]

  • 17. Susceptibility of 497 clinical isolates of gram-negative anaerobes to trovafloxacin and eight other antibiotics.
    Rotimi VO, Mokaddas EM, Jamal WY, Khodakhast FB, Verghese TL, Sanyal SC.
    J Chemother; 1999 Oct; 11(5):349-56. PubMed ID: 10632380
    [Abstract] [Full Text] [Related]

  • 18. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
    Roh KH, Kim S, Kim CK, Yum JH, Kim MS, Yong D, Lee K, Kim JM, Chong Y.
    Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
    [Abstract] [Full Text] [Related]

  • 19. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
    Aldridge KE.
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1671-4. PubMed ID: 7979307
    [Abstract] [Full Text] [Related]

  • 20. [In vitro effect of piperacillin, amoxicillin, cefoxitin and metronidazole against obligate anaerobic bacteria].
    Derriennic M, Reynaud A, Launay C, Courtieu AL.
    Presse Med; 1986 Dec 20; 15(46):2279-81. PubMed ID: 2949268
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.